ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1861

Fibrillary Glomerulonephritis Treated with Rituximab: A Case Report

Session Information

Category: Trainee Case Report

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Laquindanum, Serah Kae Labitad, Makati Medical Center, Makati City, Philippines
  • Penaranda, Eladio Miguel M., Makati Medical Center, Makati City, Philippines

Fibrillary Glomerulonephritis (FGN) is a rare primary glomerular disease first described by Rosenmann and Eliakim in 1977 present in 0.5 to 1% of native kidney biopsies defined by haphazardly arranged fibrils 10 to 30 nm in thickness deposited in the mesangium, glomerular basement membranes or both. Initially, FGN was considered to be idiopathic. However, approximately one-third have a history of malignancy, monoclonal gammopathy, autoimmune disease, hepatitis C infection or an IgM glomerular deposit disease. Prognosis is generally poor with 50% of patients developing ESRD within 6 years of presentation. The most common form of treatment is steroids with or without a second agent usually Cyclophosphamide or Rituximab. To date, there is no convincingly effective treatment but published case series reports clinical response referred to as “nonprogression” defined by stable renal function in those treated with Rituximab.

Case Description

Our patient is a 49-year old Filipino female, hypertensive, diagnosed case of Immune Complex-Mediated Glomerulonephritis presenting with elevated blood pressure and nephrotic-range proteinuria. Initial adjustment of her anti-hypertensive regimen controlled her blood pressure. Subsequently, she developed resistant hypertension and increasing proteinuria. Creatinine increased to 2.1 mg/dL from a baseline of 1 mg/dL in 12 months. A second renal biopsy was done showing fairly widespread podocyte foot process effacement and mesangial fibrillary deposits measuring 13 nm in mean diameter suggestive of Fibirillary Glomerulonephritis. Patient was worked up for an underlying malignancy, autoimmune disease and infectious causes but none turned out positive. At this time, proteinuria has increased to 7596.05 grams from 1622.08 grams with a creatinine clearance of 39.80 ml/min/1.73 m2. After discussing with the patient, she was given Rituximab as four weekly doses of 375 mg/m2 intravenously. After five months, there was significant reduction in proteinuria at 1734.32 grams with stable creatinine clearance of 31.99 ml/min/1.73 m2.


In general, FGN prognosis is poor and majority of patients progress to ESRD. Treatment options are currently limited and conclusions regarding immunosuppressive therapy cannot be drawn from limited published data. Rituximab may offer benefit particularly in patients with relatively normal baseline renal function.